In the April 8 Lancet Neurology, researchers led by Bob Olsson at the University of Gothenburg, Sweden, reported the most comprehensive meta-analysis of published Alzheimer’s disease fluid biomarker data to date. The researchers scoured literature going ...

Multiple lines of evidence have converged on the idea that toxic variants of Aβ, α-synuclein, and tau worm their way from one cell to the next, seeding the misfolding and aggregation of normal proteins as they go. In this manner, a growing number of ...

The amyloid hypothesis has dominated Alzheimer’s disease research for 25 years and generated major advances for the field. But as noted by Bart De Strooper and Eric Karran in the February 11 Cell, some of that new knowledge does not sit well with the ...

Have you ever been jolted wide awake by—biostatistics? That’s what happened on the last morning of the Clinical Trials on Alzheimer’s Disease conference held November 5-7 in Barcelona, Spain. At 8 a.m., as sleepy CTADeers slowly shuffled in, Suzanne ...

Could the protein aggregates that cause neurodegeneration turn out to be the cellular equivalent of ice cubes? Scientists investigating how proteins naturally transition between gas-like solutions, condensed liquids, solidified gels, and insoluble fibrils ...

The Alzheimer's field has had its share of clinical trial flops. Now there's a push to learn from past failures. Computational scientists in pharmaceutical companies are guiding clinical trial design by first putting drug candidates through ...

To sate the brain’s voracious hunger for energy, thousands of capillaries deliver blood and oxygen to every sulcus and gyrus, and the white and gray matter in between. Herein lies a problem. The delicate cells of the brain must be protected from the ...

In the July 2 Science Translational Medicine, an international group of scientists reported how TREM2 missense mutations linked to neurodegenerative diseases impair the protein's function. The mutations prevent TREM2 from reaching the cellular ...

Researchers rely on transgenic mice to model Alzheimer's disease, but these models are far from perfect. Some can only be maintained on specific genetic backgrounds, some die young or have surprising phenotypes when crossed with other mouse lines, ...

Whether it’s a Bach concerto, Fermat's last theorem, or simply remembering the way home from the grocery store, cognition comes at a price. The brain depends on an elaborate network of blood vessels to feed its voracious appetite for oxygen and ...

See Q&A with panelists below In the April 25 Cell, Valur Emilsson at the Icelandic Heart Association and Eric Schadt at Icahn School of Medicine at Mount Sinai, New York, report that they have identified molecular networks that are perturbed in ...

See questions answered by Suzanne Hendrix As researchers push into the frontier of early-stage and preventative Alzheimer's disease clinical trials, they will have to measure whether a drug works in people who do not have dementia yet. Traditional ...

On 4 April 2013, the Alzheimer's Disease Neuroimaging Initiative biostatistics core held the first session of its two-part online training course on using ADNI data. Led by Danielle Harvey of the University of California, Davis, the session gave a ...

Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.